Key points
- Sellas' GPS vaccine meets its Phase 3 survival goal
- What Sellas' REGAL results leave out
- When Sellas plans to file with the FDA
Sellas Life Sciences (SLS) said its experimental leukemia vaccine met the main goal of its Phase 3 trial, with patients in the vaccine group living a median 24.0 months, compared with 14.7 months in the group receiving a doctor's choice of treatment.
The vaccine, galinpepimut-S, or GPS, remains investigational and hasn't been approved by the Food and Drug Administration. Sellas hasn't released the trial's secondary results and plans to meet with the FDA to discuss filing for approval, according to its Nov. 17 release.
Sellas shares traded at $19.17 at 10:21 a.m. ET on Nov. 17, up 157% from Monday's close of $7.47. They reached $34 before the market opened and traded between $16.72 and $24.89 after the opening bell.
Median survival was 9.3 months longer in the GPS group
The REGAL trial enrolled 126 patients with acute myeloid leukemia, or AML, a fast-growing cancer of the blood and bone marrow. All were in a second or later remission and couldn't undergo a stem cell transplant from a donor.
Patients were randomly assigned in equal numbers to receive GPS alone or a treatment chosen by their doctor. The comparison group could receive observation or drug therapy using a hypomethylating agent, venetoclax, low-dose cytarabine, or a combination.
Median overall survival is the estimated time at which half the patients in a group remain alive. The GPS group's median was 9.3 months longer than the comparison group's. Sellas analyzed the results after 80 patients had died, as the trial's statistical plan specified.
Sellas reported a hazard ratio of 0.59, indicating a 41% lower estimated hazard of death in the GPS group. A hazard ratio compares the rate of deaths over time; it doesn't mean 41% fewer patients died. The two-sided p-value was 0.035, below the 0.05 threshold commonly used for statistical significance.
Sellas said GPS was generally well tolerated and that no new safety signals were found. Most treatment-related side effects were mild to moderate, and injection-site reactions were the most common.
GPS targets a protein called WT1
GPS is designed to get the immune system's T cells to attack cancer cells that carry WT1, a protein found in AML and in a range of other blood cancers and solid tumors. It's made of four peptides, short pieces of the WT1 protein, chosen to work across multiple HLA types, the immune markers that vary from person to person. In REGAL, it was tested as maintenance therapy, a treatment given to keep a patient in remission.
Sellas licenses GPS from Memorial Sloan Kettering Cancer Center, where it was discovered in the lab of David A. Scheinberg. Memorial Sloan Kettering, Scheinberg, and Javier Pinilla-Ibarz of Moffitt Cancer Center, a member of the trial's steering committee, have financial interests related to Sellas, the release says.
The steering committee is chaired by Hagop Kantarjian of MD Anderson Cancer Center, who is also the trial's global principal investigator. The committee said GPS addresses "a critical unmet need" for second-remission AML patients who can't get a donor transplant.
Secondary results and confidence intervals are still to come
The topline release gives no confidence intervals for the survival figures. Sellas said its full analysis of the secondary endpoints, which include leukemia-free survival and immune response, is under way. It plans to present the results at an upcoming major medical meeting and submit them for peer-reviewed publication.
REGAL was open-label, meaning patients and their doctors knew which treatment each patient received.
Sellas is aiming for a 2027 filing
Sellas plans to meet with the FDA to discuss an accelerated filing strategy. It's preparing a biologics license application, the filing that asks the FDA to approve a biologic drug, for submission in the first half of 2027. At $19.17 a share, Sellas was worth about $3.9 billion, based on about 203.9 million shares outstanding.












